New cocktail of drugs aims to shrink Hard-to-Treat throat cancer
NCT ID NCT06509009
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial is testing a combination of three drugs—nimotuzumab, toripalimab, and chemotherapy (gemcitabine/cisplatin)—as a first treatment for people whose nasopharyngeal cancer has come back or spread. The study will enroll 30 adults to see how well the combo shrinks tumors and how safe it is. It is currently recruiting participants in China.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nimotuzumab, toripalimab, gemcitabine, cisplatin
- What this could lead to
- If successful, this combination could offer a new first-line treatment option for people with recurrent or metastatic nasopharyngeal carcinoma, potentially improving tumor shrinkage and delaying disease progression.
- What could go wrong
- This is a small, early-phase (phase 2) study with only 30 participants, so results may not apply to everyone. Side effects from the drug combination could be significant, and the treatment may not work better than existing options.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA BY AJCC V8 STAGE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medcial Science and Peking Union Medical College
RECRUITINGBeijing, Beijing Municipality, 1000000, China